FDA Clearance Tracker · K230625
ReliOn Premier BLU Blood Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Aug 10, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Aug 10, 2023
Substantially Equivalent
Time to decision
157 days
Received Mar 6, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K230625
- Device name
- ReliOn Premier BLU Blood Glucose Monitoring System
- Applicant
- I-Sens, Inc.
- Applicant location
- Seoul, KR
- Received
- Mar 6, 2023
- Decided
- Aug 10, 2023
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1345
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NBW. The earliest in FDA's data is K010403, decided Mar 26, 2001.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K230625
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for I-Sens, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260689 · Decided Oct 2, 2026 · 213 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
- LDE4 Lancing Device510(k)
K222656 · Decided Nov 23, 2022 · 82 days after receipt
Device type: Multiple Use Blood Lancet For Single Patient Use Only (QRL) · General & Plastic Surgery
K201394 · Decided Oct 5, 2021 · 496 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.